early Breast Cancer


KATHERINE, PHERGain (ASCO23), KEYNOTE-522, ALEXANDRA/IMpassion030, KEYNOTE-756 (ESMO&SABCS), CheckMate-7FL
SABCS 2023
YiR in EBC #1: New data in HER2+ and Immunotherapy in…


SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304, Oxford analyses ASCO23, monarchE, NATALEE, POSITIVE (SABCS22 &23)
SABCS 2023
YiR in EBC #2: De-escalating therapy in locoregional…
advanced Breast Cancer


BEGONIA, SAFIR02-Breast, HER2CLIMB02, KATHERINE, COMPASS, DESTINY-Breast -01, -02, -03, TULIP, monarcHER
SABCS 2023
YiR in ABC #1: Exciting new data for first line mTNBC,…


SONIA, monarch3, PARSIFAL-long, INAVO120, RIGHT-Choice, PALMIRA, EMERALD, CAPItello291
SABCS 2023
YiR in ABC #2: New data on treatment in metastatic HR+…


DESTINY-Breast 04, TROPiCS-02, TROPION-Breast01
SABCS 2023
YiR in ABC #3: Exciting new data on ADCs in HR+ breast…
EBC HR+ HER2-


ADAPTcycle
SABCS 2023
ADAPTcycle - endocrine response


KEYNOTE-756
SABCS 2023
KEYNOTE-756 - Subgroup analysis


monarchE
SABCS 2023
cTDNA analyses in monarchE


NATALEE
SABCS 2023
Final iDSF analysis in NATALEE


CheckMate756, KEYNOTE-756, POSITIVE
SABCS 2023
SABCS23 highlights in early breast cancer


NATALEE
SABCS 2023
An enrichment of therapy options in the endocrine…


CheckMate 7FL
SABCS 2023
CheckMate7FL - Biomarker


KEYNOTE-756
SABCS 2023
Prediction of pCR in KEYNOTE-756


CheckMate 7FL, KEYNOTE-756
SABCS 2023
Hope with CPI for luminal breast cancer
EBC HER2+


KATHERINE
SABCS 2023
T-DM1 in post-neoadjuvant therapy now also with…


KATHERINE
SABCS 2023
KATHERINE: OS improvement in HER2+ eBC


SURVIVE, SURVIVE HERoes
SABCS 2023
Change in the standard of follow-up care?
EBC TNBC


ALEXANDRA/IMpassion030
SABCS 2023
Immunotherapy for early TNBC must be neoadjuvant
EBC Pregnancy and Fertility


SABCS 2023
Pregnancy after BC is safe - also in germline BRCA+ pts


POSITIVE
SABCS 2023
Importance of the onco-fertility discussion


POSITIVE
SABCS 2023
Pregnancy despite endocrine therapy in HR+ breast…
EBC Other


SABCS 2023
Anthtracyclines in EBC: to give or not to give?
EBC multilanguage


SABCS 2023
Gravidanza dopo la diagnosi di carcinoma mammario è…


CheckMate756, KEYNOTE-756, POSITIVE
SABCS 2023
SABCS23 evidenzia il cancro al mammario in fase precoce


POSITIVE
SABCS 2023
Importância da discussão sobre onco-fertilidade


monarchE
SABCS 2023
Análisis de cTDNA en monarchE


KATHERINE
SABCS 2023
KATHERINE : amélioration de la survie globale dans le…
ABC HR+ HER2-


DESTINY-Breast08
SABCS 2023
T-DXd + endocrine therapy interesting for HR+ HER2low…


MONARCH 3
SABCS 2023
Does abemciclib lead to improved OS survival in the 1st…


MONARCH 3
SABCS 2023
SABCS23 highlights in metastatic breast cancer


FOENIX-MBC2 study
SABCS 2023
Fulvestrant + futibatinib interesting for FGFR1…


MONARCH 3
SABCS 2023
Final OS analysis in MONARCH 3


TROPION-Breast01
SABCS 2023
Dato-Dxd achieves PFS


CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant in HR+ HER2-…


MONARCH 3
SABCS 2023
Is OS important?


MONARCH 3
SACBS 2023
MONARCH 3 shows clinically relevant OS-benefit without…


PARSIFAL-LONG
SABCS 2023
Long follow-up of CDK4/6i


INAVO120
SABCS 2023
Promising data for the PIK3CA-inhibitor inavolisib


PARSIFAL-LONG
SABCS 2023
OS benefit with fulvestrant/letrozole + palbocilib is…


INAVO120
SASBCS 2023
PIK3CA-inhibitor: positive results in Phase III


PARSIFAL-LONG
SABCS 2023
Letrozole + palbo as effective as fulvestrant + palbo
ABC HER2+


HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1 interesting for specific patients


AVIATOR/TBCRC045
SABCS 2023
Avelumab appears to be effective in HER2+ mBC


HER2CLIMB-02
SABCS 2023
New potential backbone for tucatinib in mHER2+ BC


HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1: Possible role in the contemporary…


HER2CLIMB-02
SABCS 2023
Efficacy of tucatinib confirmed, but unclear for which…


ASPIRE
SABCS 2023
Effective, chemo-free combination for triple-positive…
ABC TNBC


KEYLYNK-009
SABCS 2023
KEYLYNK-009: Pembrolizumab + olaparib a well-tolerated…
ABC Loco-regional recurrence and physical activity


PREFERABLE-EFFECT
SABCS 2023
Metastatic patients can and must exercise


SENOMAC
SABCS 2023
Axillary surgery de-escalation


ICARO
SABCS 2023
Isolated tumor cells in the sentinel lymph node - does…


SENOMAC
SABCS 2023
Positive sentinel lymph node after mastectomy


NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Axillary radiotherapy can be omitted in T3N1 BC pts


SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Rethinking management of the axilla


PREFERABLE-EFFECT
SABCS 2023
Physical acitivity improves QoL in advanced BC
ABC Other


ADAPTcycle
SABCS 2023
Poster insights: PO4-01-10 ADAPTcycle


OLAnzaPiNE
SABCS 2023
Low-dose olanzapine more favorable in the prophylaxis…
ABC multilanguage


MONARCH 3
SABCS 2023
SABCS23 evidenzia nel cancro al mammario metastatico


SENOMAC
SABCS 2023
Desescalada de cirugía axilar


HER2CLIMB-02
SABCS 2023
Tukatynib skuteczny, ale czy umiemy określić jego…


PARSIFAL-LONG
SABCS 2023
La supervivencia obtenida con palbociclib y…


INAVO120
SABCS 2023
Inhibiteur de PIK3CA: résultats positifs en phase III


PREFERABLE-EFFECT
SABCS 2023
L'attività fisica migliora la qualità di vita nel…


NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
La radioterapia ascellare può essere omessa nelle…


TROPION-Breast01
SABCS 2023
Dato-Dxd consigue PFS


CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant nel carcinoma…


SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Duże zmiany w leczeniu pachy


HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1: Possibile un ruolo nello scenario…


CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant dans le cancer…
General Session 1


HER2CLIMB-02
SABCS 2023
New and good therapy options for HER2+ patients


MONARCH 3
SABCS 2023
No significant OS - but what is the impact on clincial…


CheckMate-7FL, Keynote-756, ALEXANDRA/IMpassio030, KEYLYNK-009
SABCS 2023
Immunotherapy and combination therapies for HR+/HER2-…
General Session 2


POSITIVE
SABCS 2023
Pregnancy is safe after endocrine therapy


OPBC05/EUBREAST-14R/ICARO, SENOMAC
SABCS 2023
DE-escalation of the axillary interverntion after…


NRG Oncology, NSABP B-51, RTOG 1304
SABCS 2023
De-escalation of radiotherapy after neoadjuvant therapy


TROPION-Breast01
SABCS 2023
Good balance between benefits and side effect - but not…
General Session 3


Katherine
SABCS 2023
OS and final iDFS data - confirming data but risk and…


NATALEE, monarchE
SABCS 2023
Final iDFS data - is everything clear yet?


INAVO120
SABCS 2023
PI3K inihbitor Inavolisib shows improved PFS - one step…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!